Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trogarzo IV Push and Intramuscular Injection in HIV-1 Patients
NCT03913195Phase 3Completed
- Sponsor
- TaiMed Biologics
- Start
- May 2019
- Primary completion
- Oct 2022
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label trial of ibalizumab in human immunodeficiency virus type 1 infection (HIV-1) (5 arms), sponsored by TaiMed Biologics. Primary endpoints: Safety of Trogarzo Given as IV Push Over 30 Seconds at 12 weeks, Pharmacokinetics Bridge for IV Push and IV Infusion (Ctrough) at Day 85 and 3 more. Started May 2019; status: completed.
02
Drugs
ibalizumab
03
Conditions
human immunodeficiency virus type 1 infection (HIV-1)
Beyond the preview
Go deeper on NCT03913195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03913195.